Related Experiment Video
Updated: Feb 21, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Cetuximab has an inhibitory effect on cell motility in SCC-4 oral squamous cell carcinoma cell line
L M Furtado1, I C Da Silveira1, A C D M Carneiro1
1Structural Biology Department, Institute of Natural and Biological Sciences, Federal University of TriânguloMineiro, Uberaba, MG, Brazil.
Abstract:
Cetuximab is a chimeric monoclonal antibody that acts as a competitive antagonist, by binding to EGFR. This cell signalling pathways regulates tumor progression. The oral squamous cell carcinoma undergoes to regional spreading and distant metastasis. This study aimed to evaluate the effect of treatment with Cetuximab on cell migration and invasion in OSCC cells, by using the SCC-4 cell line. Cell migration and cell invasion assay were performed and actin cytoskeleton of control and treated with Cetuximab cells were evaluated. Differences were considered significant when p<0.05.Cetuximab inhibited the migration of SCC-4 cells at three concentrations: 1 µg/mL, 50 µg/mL and 100 µg/mL (p<0.0001) in a dose-dependent manner. The number of SCC-4 treated cells with 1 μg/mL that migrated through the membrane was statistically different from 50 μg/mL (p<0.001) and 100 μg/mL (p<0.0001), and between 50 μg/mL and 100 μg/mL (p<0.01). Cetuximab 50 μg/mL inhibited cell invasion through the MatrigelTM compared with SCC-4 control cells (p<0.01). Cetuximab 50 μg/mL affected the organization of the actin cytoskeleton. Cetuximab has an inhibitory effect on actin cytoskeleton organization, cell migration and invasion, suggesting that Cetuximab treatment can be important to avoid oral squamous cell carcinoma metastasis.
Insights
Cetuximab effectively inhibited oral squamous cell carcinoma (OSCC) cell migration and invasion in a dose-dependent manner. This monoclonal antibody also disrupted the actin cytoskeleton, suggesting its potential in preventing OSCC metastasis.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Oral squamous cell carcinoma (OSCC) is characterized by regional spreading and distant metastasis.
- Epidermal Growth Factor Receptor (EGFR) signaling pathways are crucial in regulating tumor progression.
- Cetuximab, a monoclonal antibody targeting EGFR, is a potential therapeutic agent.
Purpose of the Study:
- To investigate the effects of Cetuximab on cell migration and invasion in OSCC.
- To evaluate the impact of Cetuximab on the actin cytoskeleton organization in OSCC cells.
Main Methods:
- Utilized the SCC-4 cell line for oral squamous cell carcinoma studies.
- Performed cell migration and invasion assays.
- Assessed actin cytoskeleton organization in control and Cetuximab-treated cells.
Main Results:
- Cetuximab significantly inhibited SCC-4 cell migration in a dose-dependent manner across tested concentrations (1, 50, 100 µg/mL).
- A significant reduction in cell invasion through MatrigelTM was observed with Cetuximab (50 µg/mL).
- Cetuximab treatment affected actin cytoskeleton organization in SCC-4 cells.
Conclusions:
- Cetuximab demonstrates an inhibitory effect on OSCC cell migration and invasion.
- The disruption of the actin cytoskeleton by Cetuximab may contribute to its anti-metastatic potential.
- Cetuximab treatment holds promise for preventing metastasis in oral squamous cell carcinoma.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
